

# Srividya Swaminathan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11540887/srividya-swaminathan-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

657  
citations

8  
h-index

21  
g-index

21  
ext. papers

762  
ext. citations

10.7  
avg, IF

2.89  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 20 | BCL6 enables Ph <sup>+</sup> acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , <b>2011</b> , 473, 384-8  | 50.4 | 154       |
| 19 | Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , <b>2015</b> , 16, 766-774  | 19.1 | 121       |
| 18 | BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 1209-21   | 16.6 | 89        |
| 17 | BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , <b>2013</b> , 19, 1014-22   | 50.5 | 82        |
| 16 | Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , <b>2015</b> , 28, 114-28  | 24.3 | 78        |
| 15 | Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E2219-28 | 11.5 | 64        |
| 14 | Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. <i>Immunological Reviews</i> , <b>2015</b> , 263, 192-209  | 11.3 | 27        |
| 13 | BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. <i>Trends in Immunology</i> , <b>2014</b> , 35, 131-7   | 14.4 | 25        |
| 12 | Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2021</b> , 138, 1465-1480   | 2.2  | 7         |
| 11 | A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. <i>Scientific Reports</i> , <b>2021</b> , 11, 1341   | 4.9  | 2         |
| 10 | Gas7 Induces The Proliferation Of Ph <sup>+</sup> ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25 <sup>high</sup> Small Pre-B Cells. <i>Blood</i> , <b>2013</b> , 122, 2506-2506             | 2.2  | 1         |
| 9  | Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications. <i>STAR Protocols</i> , <b>2021</b> , 2, 100874   | 1.4  | 0         |
| 8  | Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. <i>Cancer &amp; Metabolism</i> , <b>2021</b> , 9, 31  | 5.4  | 0         |
| 7  | IL7R $\beta$ Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia. <i>Blood</i> , <b>2010</b> , 116, 26-26  | 2.2  |           |
| 6  | Infectious Origins of Childhood Leukemia. <i>Blood</i> , <b>2011</b> , 118, 751-751   | 2.2  |           |
| 5  | BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 562-562  | 2.2  |           |
| 4  | BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , <b>2012</b> , 120, 1300-1300  | 2.2  |           |

- 3 Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. *Blood*, **2012**, 120, 1352-1352 2.2
- 2 Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 519-519 2.2
- 1 The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. *Blood*, **2013**, 122, 836-836 2.2